Field Medical announced the presentation of clinical data from the first-in-human study of its FieldForce pulsed field ...

Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac Catheter System using Nanosecond Pulsed Field Ablation energy. Presented at ...

Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking ...

Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial ...

At 1 year, nearly 80% of patients with atrial fibrillation treated with an FDA-approved spherical pulsed field ablation ...

The system enters a field that sees PFA catheters largely displacing thermal modalities for catheter ablation of AF.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary vein isolation with pulsed field ablation may cause less neurocardiac damage vs. cryoballoon ablation.

Catheter-based pulmonary vein isolation is an effective treatment for paroxysmal atrial fibrillation. Pulsed field ablation, which delivers microsecond high-voltage electrical fields, may limit damage ...

Please provide your email address to receive an email when new articles are posted on . AF ablation with a novel contact force-sensing pulsed field catheter was safe and acutely effective. Three-month ...

A novel pulsed-field ablation system, with the Varipulse catheter and the Trupulse generator (Biosense Webster), appeared to treat patients with drug-refractory paroxysmal atrial fibrillation (AF) ...